Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply

Bjørn H Grønberg¹, Seppo Wang Langer², Jan Nyman³, Tarje Onsøien Halvorsen⁴

Affiliations

¹ Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. Electronic address: bjorn.h.gronberg@ntnu.no.
² Department of Oncology, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
³ Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁴ Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

PMID: 34087132
DOI: 10.1016/S1470-2045(21)00291-6

Comment

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply

Bjørn H Grønberg et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e222.

doi: 10.1016/S1470-2045(21)00291-6.

Authors

Bjørn H Grønberg¹, Seppo Wang Langer², Jan Nyman³, Tarje Onsøien Halvorsen⁴

Affiliations

¹ Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. Electronic address: bjorn.h.gronberg@ntnu.no.
² Department of Oncology, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
³ Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁴ Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

PMID: 34087132
DOI: 10.1016/S1470-2045(21)00291-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

BHG has received research funding from Roche and AstraZeneca, and honoraria from Roche, AstraZeneca, Pierre Fabre, Takeda, Eli Lilly, Bristol Myers Squibb, Bayer, and Novartis, outside the submitted work. All other authors declare no competing interests.

Comment on

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Grønberg BH, Killingberg KT, Fløtten Ø, Brustugun OT, Hornslien K, Madebo T, Langer SW, Schytte T, Nyman J, Risum S, Tsakonas G, Engleson J, Halvorsen TO. Grønberg BH, et al. Lancet Oncol. 2021 Mar;22(3):321-331. doi: 10.1016/S1470-2045(20)30742-7. Lancet Oncol. 2021. PMID: 33662285 Clinical Trial.
Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
Levy A, Le Péchoux C, Faivre-Finn C. Levy A, et al. Lancet Oncol. 2021 Jun;22(6):e220. doi: 10.1016/S1470-2045(21)00255-2. Lancet Oncol. 2021. PMID: 34087130 No abstract available.
Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer.
Xie L, Fan X, Qian B. Xie L, et al. Lancet Oncol. 2021 Jun;22(6):e221. doi: 10.1016/S1470-2045(21)00275-8. Lancet Oncol. 2021. PMID: 34087131 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply

Affiliations

Twice-daily chemoradiotherapy in limited-stage small-cell lung cancer - Authors' reply

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical